Reply to A.R. Khaki et al

Abstract

We thank the authors Khaki et al 1 for their well-written and poignant editorial on our review "Immunotherapy management in special cancer patient populations" published in JCO Oncology Practice earlier this year. We appreciate the fact that the authors have also concluded that immune checkpoint inhibitors (ICIs) are likely safe and effective for the special cancer patient populations that are commonly excluded from clinical trials; however, they have expressed reservations for patients with poor performance status.